Literature DB >> 12172457

Insights from mouse models of heparin-induced thrombocytopenia and thrombosis.

Michael P Reilly1, Steven E McKenzie.   

Abstract

Heparin-induced thrombocytopenia/thrombosis (HIT/T) is the most frequent cause of drug-induced antibody-mediated thrombocytopenia, a common cause of life-and limb-threatening platelet activation and thrombosis. Although antibodies to heparin-platelet factor 4 (PF4) complexes are found in essentially all patients with HIT/T, it is unclear how antibody formation is initiated, why only a small subset of these antibodies cause disease, or the mechanism by which they initiate thrombosis. The recent development of a transgenic mouse model of HIT/T showed, for the first time in vivo, that heparin, PF4, antibodies to the heparin-PF4 complex, and Fc gamma RIIA are necessary and sufficient to recapitulate the severe thrombocytopenia and thrombosis seen in patients. This model can be expanded to systematically study individual factors important to HIT/T development in vivo, to determine their contribution to the spectrum of human disease. Several recent papers have examined the role of other contributors, such as monocyte tissue factor, endothelial cell activation, and leukocyte-platelet aggregates in the pathogenesis of the disease. Mouse models will provide a means to test new diagnostic and therapeutic approaches. Copyright 2002 Lippincott Williams & Wilkens, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12172457     DOI: 10.1097/00062752-200209000-00002

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  5 in total

1.  Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia.

Authors:  Valerie Tutwiler; Daria Madeeva; Hyun Sook Ahn; Izabella Andrianova; Vincent Hayes; X Long Zheng; Douglas B Cines; Steven E McKenzie; Mortimer Poncz; Lubica Rauova
Journal:  Blood       Date:  2015-10-30       Impact factor: 22.113

2.  CalDAG-GEFI deficiency protects mice in a novel model of Fcγ RIIA-mediated thrombosis and thrombocytopenia.

Authors:  Moritz Stolla; Lucia Stefanini; Pierrette André; Timothy D Ouellette; Michael P Reilly; Steven E McKenzie; Wolfgang Bergmeier
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

Review 3.  Platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling and vascular integrity.

Authors:  Yacine Boulaftali; Paul R Hess; Mark L Kahn; Wolfgang Bergmeier
Journal:  Circ Res       Date:  2014-03-28       Impact factor: 17.367

Review 4.  Fcγ receptors and ligands and cardiovascular disease.

Authors:  Keiji Tanigaki; Nathan Sundgren; Amit Khera; Wanpen Vongpatanasin; Chieko Mineo; Philip W Shaul
Journal:  Circ Res       Date:  2015-01-16       Impact factor: 17.367

Review 5.  Drug-induced thrombosis: an update.

Authors:  Yuval Ramot; Abraham Nyska; Galia Spectre
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.